A biotechnology company based in Marseille, France, Vect-Horus specializes in designing molecular vectors that help deliver therapeutic molecules and imaging agents to specific organs and tissues. Recently, the company announced its participation in the Viva Technology conference, which will take place in Paris from May 22-25, 2024.
Vect-Horus has been selected by France’s National Center for Scientific Research (CNRS) as one of the 10 startups showcasing disruptive technologies at the event. At the conference, Chief Scientific Officer Jean-Manuel Pean will participate in a roundtable discussion to provide an overview of the company’s pipeline, recent advancements in technology and partnerships with companies like Novo Nordisk and Ionis Pharmaceuticals.
Founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP), UMR7051, CNRS, and Aix Marseille University, Vect-Horus employs 38 individuals primarily in research and development. The company focuses on developing vectors for targeting and delivering therapeutic and imaging agents to organs and tumors.
For more information about Vect-Horus visit their website at www.vect-horus.com or contact them at contact@vect-horus.com. For media inquiries please reach out to Emmanuelle Bettendorf for BD & Alliance Management at contact@vect-horus.com or Sophie Baumont from Cohesion Bureau for Media Relations at sophie.baumont@cohesionbureau.com
